

Special Issue

African Swine Fever Virus Vaccine Development

Message from the Guest Editors

African Swine Fever Virus is a large, enveloped double-stranded DNA virus. ASFV is a highly infectious and severe hemorrhagic disease that affects pigs, causing a wide range of clinical signs. Issues such as homologous recombination, delayed onset, and the potential for secondary infections pose significant risks, and the performance of the gene-deleted live vaccine still requires further study. While inactivated vaccines, subunit vaccines, and vector-based ASF vaccines are generally considered safer, their efficacy is not enough to protect against higher doses of virulent viruses in inoculated infections.

We must investigate the changes that occur during viral infection and the resulting pathogenesis while also focusing on vaccine research to provide a solid foundation for preventing and controlling ASF.

We welcome original research articles and reviews on topics including (but not limited to) the followings:

- **Virus infection and dissemination**
- **Pathogenicity, migratory patterns, tissue tropism, and distribution in pigs**
- **Research on immune responses and the protective effects of various types of ASF vaccines**

Guest Editors

Dr. Faming Miao
Dr. Hong Jia
Dr. Lian-Feng Li

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/232858

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).